VABOMERE Shows Higher Cure Rate in Patients with CRE Infections Vs. Best Available Therapy

Jason Pogue, PharmD, BCPS, BCIDP, contextualizes preliminary data looking at this trial and other extended-spectrum beta-lactamase (ESBL) studies, which reopens the debate around carbapenem-sparing treatment options.

Resistance-guided testing targeting a single gene mutation could let clinicians safely reintroduce ciprofloxacin for the majority of gonorrhea cases still susceptible to it, sparing ceftriaxone as resistance climbs worldwide. Lao-Tzu Allan-Blitz, MD, MPH, offers insights into his work in this area.

Lori Handy, MD, provides guidance in these areas including presentation before rash onset, when patients should be considered for the inpatient setting, and what treatment looks like.

IDSA/ESCMID panel member Henry Chambers, MD, explains why the new S aureus bacteremia guidance replaces the complicated vs uncomplicated label with risk stratification, and how the statements are akin to the stages of cancer in guiding treatment decisions associated with this bacteremia.

Staphylococcus aureus Bacteremia (SAB) causes significant morbidity and globally is the leading cause of death from bloodstream infection. This month, the IDSA and ESCMID released 7 consensus statements to assist in managing individuals with SAB. This review will focus on the adult patient population and additional information on pediatric population statements can be assessed in the guideline. Here is a closer look at Consensus Statement 2: Follow-up Blood Cultures.

With a significant increase in rabies exposures this year, Rodney Rohde, PhD, talks about seeking medical attention after animal interactions as well as clinical treatment when people have been bit or scratched.

Widespread antimicrobial use disrupts vital microbial communities that regulate Earth’s biogeochemical cycles, driving antimicrobial resistance, worsening human and environmental health, and significantly contributing to climate change.

New data from the PETERPEN trial suggest that piperacillin-tazobactam may be noninferior to meropenem for early clinical outcomes in select patients with ESBL bloodstream infections, but carbapenems remain the standard of care until final mortality results are available and fully analyzed.